#1 Clinical Trials Search in Europe

Follitropin Beta

Follitropin Beta, also known as Follistim or Puregon, is a recombinant form of follicle-stimulating hormone (FSH) used in fertility treatments. This article examines various clinical trials that have investigated the efficacy, safety, and applications of Follitropin Beta in assisted reproductive technologies and ovulation induction.

Table of Contents

What is Follitropin Beta?

Follitropin beta is a medication used to treat infertility in women. It is a type of hormone called follicle-stimulating hormone (FSH) that is made in a laboratory using genetic engineering techniques. This is why it’s sometimes referred to as “recombinant FSH” or “rFSH”.[1]

Follitropin beta is known by several brand names, including:

  • Puregon
  • Follistim
  • Primapur (a biosimilar version)[2]

How Follitropin Beta Works

Follitropin beta works by stimulating the ovaries to produce mature eggs. In a natural menstrual cycle, the body produces FSH to stimulate egg development. Follitropin beta mimics this natural process but at a higher intensity, causing multiple eggs to mature instead of just one.[3]

This medication is often used as part of fertility treatments such as in vitro fertilization (IVF) or intrauterine insemination (IUI). These are procedures where eggs are either fertilized outside the body (IVF) or sperm is placed directly into the uterus (IUI) to increase the chances of pregnancy.

Conditions Treated with Follitropin Beta

Follitropin beta is used to treat various fertility issues, including:

  • Anovulation: A condition where a woman’s ovaries do not release an egg regularly
  • Oligoovulation: Infrequent or irregular ovulation
  • General infertility issues
  • Preparation for IVF or other assisted reproductive technologies[4]

How Follitropin Beta is Administered

Follitropin beta is typically given as a subcutaneous injection (an injection just under the skin) or sometimes as an intramuscular injection. The dosage and duration of treatment can vary depending on the individual patient and their specific fertility treatment plan.[3]

Some common administration protocols include:

  • Daily injections of 50-375 IU (international units) for 7-12 days
  • Starting dose of 150-225 IU for the first 4 days, then adjusting based on the patient’s response
  • Treatment continuing until ultrasound shows mature follicles (usually around 18mm in size)[4]

After follitropin beta treatment, doctors often give another hormone called human chorionic gonadotropin (hCG) to trigger final egg maturation and ovulation.

Effectiveness of Follitropin Beta

The effectiveness of follitropin beta can be measured in several ways:

  • Number of eggs retrieved: This is often used as a primary measure of the medication’s effectiveness. More eggs generally mean more chances for successful fertilization and pregnancy.[1]
  • Pregnancy rates: Studies look at how many women become pregnant after treatment with follitropin beta.
  • Live birth rates: This is the ultimate goal of fertility treatment.[5]

The exact success rates can vary widely depending on many factors, including the woman’s age, the cause of infertility, and other aspects of the fertility treatment plan.

Potential Side Effects

Like all medications, follitropin beta can cause side effects. Some potential side effects include:

  • Injection site reactions (redness, pain, or swelling where the injection was given)
  • Ovarian hyperstimulation syndrome (OHSS): A condition where the ovaries become swollen and painful
  • Multiple pregnancies (twins, triplets, etc.)
  • Headache
  • Abdominal pain or bloating[1]

It’s important to discuss all potential risks and side effects with your doctor before starting treatment.

Comparison to Other Fertility Medications

Follitropin beta is one of several similar medications used in fertility treatments. Others include:

  • Follitropin alfa: Another form of recombinant FSH, very similar to follitropin beta
  • Corifollitropin alfa (brand name Elonva): A long-acting form of FSH that can be given as a single injection instead of daily injections[6]
  • Menotropins: A mixture of FSH and luteinizing hormone (LH) derived from the urine of postmenopausal women

Studies have compared these different medications, looking at factors like the number of eggs retrieved, pregnancy rates, and side effects. In general, follitropin beta has been found to be effective and safe, with results comparable to other gonadotropins.[5]

Aspect Details
Main Uses Ovarian stimulation in IVF, Ovulation induction in anovulation/oligoovulation
Administration Daily subcutaneous injections, dosage varies (typically 50-375 IU)
Treatment Duration Usually 7-20 days, depending on individual response
Primary Outcomes Number of oocytes retrieved, Pregnancy rates, Ovulation rates
Secondary Outcomes Hormone levels, Follicle development, Embryo quality, Live birth rates
Safety Monitoring OHSS incidence, Multiple pregnancy rates, Adverse events
Comparisons Other gonadotropins, Newer formulations (e.g., corifollitropin alfa)
Patient Populations Women undergoing IVF, Women with anovulation/oligoovulation

FAQ

  • What is Follitropin Beta used for in fertility treatments? Follitropin Beta is used for ovarian stimulation in assisted reproductive technologies like in vitro fertilization (IVF) and for ovulation induction in women with anovulation or oligoovulation due to hypothalamus-pituitary dysfunction.
  • How is Follitropin Beta administered? Follitropin Beta is typically administered as daily subcutaneous injections. The dosage and duration of treatment vary depending on the individual patient's response and the specific fertility protocol being used.
  • What are some common outcomes measured in Follitropin Beta clinical trials? Common outcomes include the number of oocytes retrieved, pregnancy rates, ovulation rates, hormone levels, follicle development, and the incidence of side effects such as ovarian hyperstimulation syndrome (OHSS).
  • How does Follitropin Beta compare to other fertility medications? Clinical trials have compared Follitropin Beta to other gonadotropins and newer formulations like corifollitropin alfa. These studies assess factors such as efficacy, safety, and patient convenience in different fertility treatment protocols.
  • What are some potential side effects of Follitropin Beta? Potential side effects can include injection site reactions, ovarian hyperstimulation syndrome (OHSS), and multiple pregnancies. Clinical trials often monitor these and other adverse events to assess the safety profile of Follitropin Beta.

Ongoing Clinical Trials on Follitropin Beta

  • Study on Corifollitropin Alfa and Follitropin Beta for Women with Infertility Undergoing Ovarian Stimulation with Medroxyprogesterone Acetate

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Fertility Preservation Using Tamoxifen, Follitropin Beta, Cetrorelix and Choriogonadotropin Alfa in Women with Breast Cancer Before Chemotherapy

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Corifollitropin Alfa and Modified Natural Cycles for Women with Subfertility and Low Ovarian Response

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study on Pregnancy Rates in Women with Polycystic Ovary Syndrome Using Letrozole and Gonadotropins

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing Corifollitropin Alfa and Progestin Primed Ovarian Stimulation for Women with Subfertility Undergoing Elective Fertility Preservation or Genetic Testing

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study on the Effects of Follitropin Beta and Corifollitropin Alfa for Patients with Subfertility Undergoing ICSI Treatment

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study on Infertility: Comparing Corifollitropin Alfa and Follitropin Beta for Women Undergoing Elective Fertility Preservation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Follitropin Beta: A recombinant form of follicle-stimulating hormone (FSH) used in fertility treatments to stimulate ovarian follicle development.
  • In Vitro Fertilization (IVF): A fertility treatment where eggs are retrieved from the ovaries and fertilized with sperm in a laboratory before being transferred back to the uterus.
  • Ovulation Induction: The process of using medications to stimulate the ovaries to produce and release eggs.
  • Gonadotropin: Hormones that stimulate the gonads (ovaries in women, testes in men) to produce sex hormones and gametes.
  • Anovulation: A condition where a woman does not ovulate or release an egg during her menstrual cycle.
  • Oligoovulation: A condition where a woman ovulates infrequently or irregularly.
  • Ovarian Hyperstimulation Syndrome (OHSS): A potential complication of fertility treatments where the ovaries become swollen and painful due to excessive stimulation.
  • Subcutaneous Injection: An injection given into the fatty tissue just beneath the skin.
  • Oocyte: An immature egg cell in the ovary.
  • Follicle: A fluid-filled sac in the ovary that contains a developing egg.
  • Human Chorionic Gonadotropin (hCG): A hormone used in fertility treatments to trigger final egg maturation and ovulation.
  • Luteal Support: The use of hormones, typically progesterone, to support the uterine lining after ovulation or embryo transfer in fertility treatments.
  • Estradiol: A form of estrogen hormone that plays a crucial role in the development of female reproductive tissues.
  • Progesterone: A hormone that prepares the uterus for pregnancy and supports early pregnancy.
  • Blastocyst: An embryo that has developed for 5-6 days after fertilization and is ready for implantation.

References

  1. https://clinicaltrials.gov/study/NCT03228680
  2. https://clinicaltrials.gov/study/NCT04854707
  3. https://clinicaltrials.gov/study/NCT00920634
  4. https://clinicaltrials.gov/study/NCT00920361
  5. https://clinicaltrials.gov/study/NCT04142190
  6. https://clinicaltrials.gov/study/NCT02471677